HOME >> MEDICINE >> NEWS
New data on the effect of Atacand(R) on NYHA class in a broad spectrum of heart failure patients

Mlndal, Sweden, 9 March 2004 Data presented today at the American College of Cardiology (ACC) annual meeting add weight to the evidence shown in the original publications from the CHARM* Programme of the effects of Atacand (candesartan cilexetil) in chronic heart failure (CHF) patients. The results from further analysis of the data add further support for the CHARM study as a landmark clinical research programme.

Importantly, one analysis1 found that New York Heart Association (NYHA) functional class improved in a broad spectrum of CHF patients treated with Atacand. Of all CHARM patients, 35.4% taking Atacand improved in NYHA functional class, 55.6% remained unchanged and 9% worsened. This compared with 32.5%, 57.5% and 10.3% respectively in the placebo group (p=0.004). These findings were supported by a favourable change in the Overall Treatment Evaluation in the Atacand group compared to the placebo group (p=0.01).

Commenting on this additional analysis, Professor John McMurray, principal investigator in the CHARM-Added study, Glasgow University and Western Infirmary, Glasgow, Scotland, said "Improving symptomatic well-being is a key objective of heart failure treatment. NYHA functional classification is the most widely used and validated measure of symptomatic limitation in CHF. That candesartan has been shown to improve NYHA functional class across the broad spectrum of CHF investigated in the CHARM Programme will have significant implications for clinical practice. These findings are consistent with a reduction in CHF hospitalisations".

A further analysis suggests that the development of atrial fibrillation (AF) in some patients with symptomatic chronic heart failure may also be reduced. Of the 7,601 heart failure patients in CHARM, 72.6% did not have atrial fibrillation (AF) at baseline. This new analysis found that, in the patients randomised to Atacand, new incidence of AF during the trial was 6.5%, compared to 7.9% in the place
'"/>

Contact: Mark Chamberlain
mark.chamberlain@ketchum.com
44-207-611-3649
Ketchum
9-Mar-2004


Page: 1 2

Related medicine news :

1. Strategy effective against drug resistant tuberculosis
2. Study shows patch therapy may be as effective as oral medications
3. Chronic pain treatments more effective when taken together, new study shows
4. Geodon effective in psychiatric emergencies; Sharply reduces time in restraints
5. Brain activity prior to treatment flags vulnerability to antidepressant side effects
6. Improving access to healthy food has little effect on diet
7. Storage time and temperature effects nutrients in spinach
8. Costs of antidepressants could have funded effective alternatives
9. New ways to design safer & more effective topical (transdermal) drug delivery announced in the PNAS
10. Government wasting your taxpayer money on ineffective drug cure
11. Neurobehavioral function during coma, stroke rehabilitation effective for elderly

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
Breaking Medicine Technology:
Cached News: